Drilldown: Medicines
Appearance
Medicines > halflife
:
1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"'
or
~12 hours
or
~20 hours 
:
1.5-2 hours (longer in renal failure)'"`UNIQ--ref-00000222-QINU`"'
or
~12 hours
or
~20 hours 
Use the filters below to narrow your results.
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Excessive daytime sleepiness or cataplexy in adults with narcolepsy (FDA-approved August 2019) (1) ·
Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) ·
'"`UNIQ--vote-0000021C-QINU`"', '"`UNIQ--vote-0000021D-QINU`"', '"`UNIQ--vote-0000021E-QINU`"', '"`UNIQ--vote-0000021F-QINU`"', '"`UNIQ--vote-00000220-QINU`"', '"`UNIQ--vote-00000221-QINU`"' (1)
None (1) ·
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) ·
20-40 mg PO/IV; titrate by clinical response. In diuretic-resistant heart failure or CKD, doses to 200 mg or higher may be needed (1) ·
Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed. (1)
Avoid where possible; can reduce uteroplacental perfusion and produce neonatal electrolyte disturbance. Reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category C (1) ·
Limited data; avoid (1) ·
Limited data; pitolisant may reduce hormonal contraceptive efficacy (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.

